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BACKGROUND:The human kallikrein-related peptidase family consists of 15 genes. Twelve of these genes are overexpressed in ovarian
cancer and may represent potential markers for diagnosis, prognosis, and/or response to treatment. The aim of this study was to
determine the prognostic significance of kallikrein-related peptidase 6 (KLK6) and kallikrein-related peptidase 13 (KLK13) in epithelial
ovarian cancer by quantifying gene expression levels with tumour pathology and patient survival data.
METHODS: Total RNA was isolated from 106 patients diagnosed with primary ovarian cancer, as well as 8 normal ovary controls.
Samples were analysed by quantitative real-time PCR for KLK6 and KLK13 expression. Correlation between kallikrein gene
expression and clinical characteristics was evaluated with the w
2-test. Survival analysis was performed using Kaplan–Meier and Cox
proportional hazards regression models.
RESULTS: Expression levels of both KLK6 and KLK13 mRNA were significantly increased in invasive cancers relative to normal ovaries
(P¼0.002 and 0.039 respectively). High KLK6 and KLK13 expression was an indicator of poor prognosis, with patients having a
shorter recurrence-free survival (P¼0.002 and 0.027 respectively). High KLK6 expression was also significantly associated with lower
overall survival (P¼0.011). When subjected to multivariate analysis, patients with either high KLK6 or KLK13 were 3- and 2.2-fold,
respectively, more likely to have a recurrence than patients with low kallikrein expression.
CONCLUSION: These data show increased mRNA expression of KLK6 and KLK13 in ovarian cancer compared to normal ovarian
tissues. High KLK6 or KLK13 expression in primary ovarian tumours can significantly predict prognosis in terms of recurrence-free
survival and overall survival. In all, this study shows KLK6 and KLK13 as potential biomarkers and may be therapeutic targets for
treatment of ovarian cancer.
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Ovarian carcinoma, known as ‘the disease that whispers,’ is the
most lethal of all the gynaecological malignancies. Annually,
approximately 23000 new cases and 14000 deaths in the United
States are due to ovarian cancer (Holschneider and Berek, 2000).
This malignancy presents a great clinical challenge as it is often
diagnosed in the late stages due to its anatomical location and
relative asymptomatic occurrence (Holschneider and Berek, 2000).
Approximately 75% of patients are diagnosed in late stage disease
(stage III/IV) and have a 5-year survival rate of only 15–20%,
compared to a 80–90% 5-year survival rate when diagnosed in the
early stages (stage I/II; Schink, 1999). The disease is treatable and
in most cases curable if diagnosed in the early stages.
Recently, a family of serine proteases has been identified on
human chromosome 19q13 and named the human kallikrein-
related peptidase family (KLK; Yousef and Diamandis, 2003). The
family consists of 15 genes, of which 12 (KLK2, KLK3, KLK4, KLK5,
KLK6, KLK7, KLK8, KLK10, KLK11, KLK13, KLK14, and KLK15)
appear to be overexpressed in ovarian cancer. As been shown for
prostate-specific antigen (PSA/KLK3) in prostate cancer, these may
represent potential novel biomarkers for ovarian carcinoma (Borgono
and Diamandis, 2004). This study focuses on two members of the
kallikrein-related peptidase family, KLK6 and KLK13.
Kallikrein-related peptidase 6 (KLK6) was initially identified by
three different groups who named it protease M in breast cancer
(Anisowicz et al, 1996), zyme in Alzheimer’s disease (Little et al,
1997), and neurosin in colon adenocarcinoma (Yamashiro et al,
1997). KLK6 is reported to have differential expression in ovarian,
breast, uterine, and colon cancers (Anisowicz et al, 1996; Tanimoto
et al, 2001; Hoffman et al, 2002; Ogawa et al, 2005; Santin et al,
2005). KLK6 is overexpressed at both the gene and protein levels
in ovarian cancer and has been associated with poor patient
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sprognosis (Diamandis et al, 2000a; Tanimoto et al, 2001;
Kountourakis et al, 2008). Recently, KLK6 has been implicated in
the loss of cell–cell contact and promotion of cell proliferation,
migration, and invasion in keratinocytes (Klucky et al, 2007). With
the involvement in these biological functions, the overexpression
of KLK6 in ovarian cancer suggests it may be involved in pro-
moting cancer invasion and metastasis. In vitro assays have shown
that recombinant KLK6 proteins are capable of extracellular matrix
(ECM) protein digestion and neutralising KLK6 antibodies can
decrease the rate of migration of ovarian cancer cell lines, further
supporting this hypothesis (Ghosh et al, 2004).
Kallikrein-related peptidase 13 (KLK13) was first identified as
downregulated in breast cancer tissues and cell lines (Yousef et al,
2000). However, 50% of malignant ovarian tissues had increased
KLK13 expression relative to nearly undetectable levels in normal
or benign tissue (Kapadia et al, 2003). In addition, Scorilas et al
(2004) found high levels of KLK13 in early stage cancers and
consequently associated high KLK13 with a better prognosis.
Similar to KLK6, KLK13 can degrade major components of the
ECM and when treated with an anti-KLK13 antibody, an ovarian
cancer cell line showed decreased migratory capacity (Kapadia
et al, 2004). On the basis of these previously observed KLK6
and KLK13 effects on ovarian cancer cells, the aim of this study
was to evaluate the prognostic significance of KLK6 and KLK13 in
epithelial ovarian cancer by quantifying gene expression levels and
correlating them with clinical variables and patient survival data.
MATERIALS AND METHODS
Ovarian cancer samples
The study analysed formalin-fixed, paraffin-embedded ovarian
tissues from 106 cases of sporadic ovarian carcinoma diagnosed in
the province of Newfoundland and Labrador, Canada between
1983 and 2002. Eight normal ovary samples were also obtained for
comparison. Tissues were collected from pathology archives and
selected based on hematoxylin and eosin stains reviewed by a
pathologist. Clinical staging was performed using the standard
International Federation of Gynecology and Obstetrics staging,
with tumours graded as borderline, well differentiated (grade I),
moderately differentiated (grade II), or poorly differentiated
(grade III). Clinical history was obtained by review of patients’
medical records in accordance with Memorial University’s human
investigation committee protocol.
Medical treatment of patients consisted of a total abdominal
hysterectomy, bilateral salpingo-oophorectomy, omentectomy,
and tumour staging. When cancer was not in stage 1A grade 1
or borderline, patients went on to receive chemotherapy. As the
scope of this study spans from 1983 to 2002, chemotherapy
regimes changed over this time. Before 1995/96 patients received
cisplatin and cyclophosphamide, given for 6–9 cycles, at the
discretion of the physician. After 1995/96 with the introduction of
taxanes, treatments involved the combining of taxol with either
cisplatin or carboplatin. A small number of patients with late stage
(3C and 4) disease before 1998 were also treated with chemother-
apy as a neoadjuvant pre-surgery.
Immunohistochemistry
Sections were cut 4mm thick and dried on glass slides overnight.
Sections were deparaffinised in xylene and re-hydrated through
decreasing graded alcohols. Antigen retrieval was performed using
a pressure cooker for 10min in citrate buffer (pH 6.0). Slides were
incubated overnight in primary antibody, washed twice with
phosphate-buffered saline (pH 7.4) followed by either of two
detection methods. Detection of KLK6 immunocomplex was
carried out using Envision (Dako, Mississauga, Ontario, Canada),
whereas localisation of KLK13 immunocomplex was performed
with LSABþ, Link, and streptavidin reagents (Dako). Immune
complexes were visualised by incubating with diaminobenzidine
and sections were counterstained with hematoxylin. Immunoloca-
lisation of KLK6 was carried out using a rabbit polyclonal
antibody (Diamandis et al, 2000b), whereas KLK13 localisation
was carried out using a mouse monoclonal antibody, clone 33.1
(Kapadia et al, 2003).
Quantitative real-time PCR
Five 10mM sections were cut from paraffin-embedded tissues for
nucleic acid isolation. Total RNA was extracted using the High
Pure RNA Paraffin kit (Roche, Indianapolis, IN, USA) according to
the manufacturer’s protocol. Total RNA concentration was
determined spectrophotometrically at 260nM and samples were
stored at  801C. The presence of high molecular weight total RNA
was determined using a NanoDrop 1000 Spectrophotometer
(NanoDrop Technologies Inc., Wilmington, DE, USA) and
ethidium bromide staining of samples using formaldehyde gel
electrophoresis. cDNA was synthesised using 2mg total RNA
and Superscript First-Strand Synthesis System for RT–PCR
(Invitrogen, Carlsbad, CA, USA) with random hexamers to ensure
representation of all mRNA independent of polyadenylated tail.
Quantitative real-time polymerase chain reaction (qRT-PCR)
was performed using the ABI Prism 7000 (Applied Biosystems,
Foster City, CA, USA). Primer/probe sets were purchased as pre-
made TaqMan Assays on Demand for KLK13, KLK6, and
glyceraldehyde 3-phosphate dehydrogenase (GAPDH; described
in Supplementary Table 1). Thermal cycling conditions were
according to the manufacture’s protocol and all reactions were
performed in triplicate. Relative quantification was defined as the
amount of the specific mRNA normalised to a normal ovary as
determined using the comparative cycle threshold (CT) method.
The relative target gene expression was defined as 2
 DDCT, where
DDCT¼DCT normal ovary–DCT ovarian cancer. A normal ovarian
sample having the median level of expression for a specific target
gene was chosen as the calibrator sample and used to normalise
expression of all other samples (i.e. target gene expression¼1).
DCT is defined as CTt a r g e t –CT GAPDH, where the target genes were
KLK13 and KLK6. Relative to the calibrator sample, target gene
relative expression (RE) was classified as being low or high
kallikrein expression. The expression level for determining high
expressing samples was defined as one standard deviation above
the mean value for all normal ovarian RE, for each specific target
gene. Samples with an RE equal to or above this value were
classified as high expression, whereas samples below the cut-off
were classified as low expression. The cut-off for KLK6 was
determined as 5.211 RE and KLK13 as 0.981 RE. Using a standard
deviation above the normal mean RE of each target gene allowed
us to utilise the inherent variation of each target gene expression to
independently determine its cut-off value.
Statistical analysis
All statistical analysis was performed with the SPSS statistical
package for PC (version 13.0; SPSS Inc., Chicago, IL, USA). The
relationships between KLK6 and KLK13 mRNA expression and
patient clinical characteristics were analysed with a w
2-test. For
survival analysis, two end points were examined; cancer recurrence
(defined as either a local recurrence or metastasis) and death.
These end points were used to calculate the recurrence-free
survival (RFS) and overall survival (OS) respectively. Recurrence-
free survival is defined as the time from first diagnosis to the time
of first detected recurrence or metastasis. Overall survival is
defined as the time from initial diagnosis to the time of death. Two
survival models, the Kaplan–Meier and the Cox proportional
hazard regression, were used for the analysis. The Kaplan–Meier
Prognostic significance of KLK6 and KLK13
NMA White et al
1108

























smodel was used to examine survival between the patients
expressing kallikreins at low or high levels, whereas significance
was measured with the log-rank test. The Cox proportional hazard
regression model, using both univariate and multivariate models,
was used to determine the hazard ratio.
RESULTS
Immunohistochemical localisation of KLK6 and KLK13 in
ovarian carcinoma
Figure 1 illustrates the pattern of KLK6 and KLK13 localisation in
ovarian surface epithelium (OSE) and epithelial ovarian carcinoma.
Both KLK6 and KLK13 were localised in the cytoplasm of the normal
ovarian surface epithelial (Figures 1A and B). Both KLK6 and KLK13
showed staining in all types of ovarian adenocarcinoma. Shown here is
strong staining for both KLKs in serous adenocarcinoma (Figures 1C
and D), with KLK6 shown expressed in a mucinous adenocarcinoma
(Figure 1E) and KLK13 expression in a clear cell tumour (Figure 1F).
In all cases, staining was most prominent in epithelial cells, whether
they were normal surface epitheliumo rc a r c i n o m a .I m m u n o h i s t o l o -
gical evaluation of protein levels resulted in no significant associations
with clinical characteristics. The intensity of staining may not be only
because of the variation of kallikrein expression in each pathological
specimen, but also be contributed by the variations in fixing and
embedding procedures used during the processing of tissues. To
quantify the differences in expression more accurately, we extracted
total RNA from ovarian samples and analysed by qRT-PCR, com-
paring KLK expression in ovarian tumours to normal samples.
Association between Kallikrein gene expression and
clinical variables
The relationship between KLK6 and KLK13 expression levels and
clinical characteristics is summarised in Table 1. Patient ages range
from 20 to 89 years with a mean age of 60 years. Compared to patients
with low KLK6, a significantly larger proportion of patients with high
KLK6 had invasive cancer (P¼0.002) and late stage cancers
(P¼0.001). Compared to patients with low KLK13, a larger proportion
of patients with high KLK13 had invasive cancer (P¼0.039). Unlike
KLK6, KLK13 was not associated with clinical stage.
At diagnosis, 65% of all patients had serous ovarian cancer. In
supplementary analysis, when we compared serous to non-serous
ovarian cancers (mucinous, endometrioid, clear cell, and un-
known), high KLK6 expression was associated with serous
carcinomas (P¼0.001; data not shown). Interestingly, all endo-
metrioid ovarian cancers had high KLK13 expression relative to
normal ovaries, but the small sample size was unable to provide
sufficient power for a conclusive association.
KLK6 expression association with recurrence and survival
Kaplan–Meier survival curves indicated patients with high KLK6
expression were more likely to have a shorter RFS (P¼0.002,






Figure 1 KLK6 and KLK13 expression in normal ovarian surface epithelium (OSE) and epithelial ovarian cancer. The normal OSE stains positive for both
KLK6 (A) and KLK13 (B). Serous epithelial cancers express KLK6 (C) and KLK13 (D) in the cytoplasm. In a mucinous ovarian tumour, KLK6 shows strong
expression (E). KLK13 is positively expressed in a clear cell ovarian tumour (F). All photomicrographs were taken at  40 magnification.
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spatients with low KLK6 expression. These data are further
supported by the Cox regression analysis presented in Table 2.
In univariate analysis, patients with high KLK6 expression had a
greater risk of recurrence (P¼0.004) than patients with low KLK6
expressing tumours. As expected, clinical stage (Po0.001), tumour
grade (P¼0.012), and histological type (P¼0.024) were all
significant predictors of recurrence. In the multivariate model
(Table 3), high KLK6 expression remains significant as a predictor
of recurrence (P¼0.040), indicating these patients are approxi-
mately three times more likely to have a recurrence than patients
with low KLK6 expression. Overall, late clinical stage (stage III/IV)
was the strongest predictor of recurrence (P¼0.001).
When OS is examined in a Cox univariate model (Table 2), high
KLK6 expression is significantly associated with a shorter OS
(P¼0.013). As expected, clinical stage (Po0.001), tumour grade
(Po0.001), and histological type (P¼0.037) are all associated with a
shorter OS. Interestingly, patients 50 years of age or older, at the time
of diagnosis, also had a significantly shorter OS (P¼0.045) than
patients under the age of 50. When these factors were included in a
multivariate analysis (Table 3), clinical stage was the strongest
predictor of OS, patients with late stage (stage III/IV) cancers had a
four-fold increased likelihood of a shorter OS (P¼0.001) than
patients with early stage (Stage I/II) cancer. Other clinical
characteristics lost their predictive significance of OS when subjected
to multivariate analysis, including high KLK6 expression (P¼0.215).
High KLK13 expression in ovarian tumours is associated
with poor prognosis
When KLK13 expression was analysed with the Kaplan–Meier
model, patients with high KLK13 expression had a shorter RFS
than patients with low KLK13 expression (P¼0.027; Figure 3A).
Table 1 Association between KLK6 and KLK13 mRNA expression with clinicopathological data for 106 ovarian carcinoma patients and 8 normal ovaries
No. of patients (%) No. of patients (%)
Variable n KLK6 low KLK6 high P-value KLK13 low KLK13 high P-value
Age
o50 24 8 (33.3) 16 (19.5) 0.155 9 (18.8) 15 (25.9) 0.384
X50 82 16 (66.7) 66 (80.5) 39 (81.3) 43 (74.1)
Status
Normal 8 6 (20.0) 2 (2.4) 0.002 7 (12.7) 1 (1.7) 0.039
Borderline 6 3 (10.0) 3 (3.6) 4 (7.3) 2 (3.4)
Invasive 100 21 (70.0) 79 (94.0) 44 (80.0) 56 (94.9)
Histological type
Serous 69 10 (41.7) 59 (72.0) 0.073 33 (68.8) 36 (62.1) 0.082
Mucinous 15 6 (25.0) 9 (11.0) 5 (10.4) 10 (17.2)
Endometroid 6 3 (12.5) 3 (3.7) 0 6 (10.3)
Clear cell 4 1 (4.2) 3 (3.7) 2 (4.2) 2 (3.4)
Unknown 12 4 (16.7) 8 (9.8) 8 (16.7) 4 (6.9)
Clinical stage
Early (I/II) 32 14 (25.0) 18 (22.0) 0.001 16 (33.3) 16 (27.6) 0.521
Late (III/IV) 74 10 (14.7) 64 (78.0) 32 (66.7) 42 (72.4)
Tumour grade
GB/G1 21 6 (25.0) 15 (18.3) 0.468 12 (25.0) 9 (15.5) 0.223




No. events = 29
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Figure 2 Kaplan–Meier survival curves showing the proportion of patients who are recurrence free (A) and alive (B) at the given time after diagnosis.
Patients are stratified based on KLK6 expression and compared by the log-rank test. Patients whose tumours are KLK6 low are represented with the broken
line, whereas patients whose tumours are KLK6 high are represented by the solid line. n, number of patients.
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sThe strength of association between KLK13 high expressing
tumours and survival outcome is presented in a Cox regression
model (Tables 3 and 4). Univariate analysis showed high KLK13 as
a significant predictor of recurrence (P¼0.030), indicating a 2.2-
fold increased probability of recurrence compared to low KLK13
(Table 3). When KLK13 expression was examined in a multivariate
model, it retains the ability to significantly predict a shorter
RFS (P¼0.047; Table 4). Late clinical stage and serous type cancer
also significantly predict a shorter RFS (P¼0.001 and 0.024
respectively). When we examine KLK13 expression along with
other factors in a multivariate model, late clinical stage was the
only significant predictor of OS (Po0.001).
Table 2 Univariate Cox regression analysis of KLK6, KLK13, and other clinicopathological variables
RFS OS
Variable HR 95% CI P-value HR 95% CI P-value
Univariate analysis
KLK6
Low 1.00 — — 1.00 — —
High 4.59 1.61–13.08 0.004 2.06 1.16–3.63 0.013
KLK13
Low 1.00 — — 1.00 — —
High 2.19 1.08–4.46 0.030 1.33 0.83–2.19 0.231
Clinical stage
a (ordinal) 11.89 3.61–39.15 o0.001 5.91 2.82–12.35 o0.001
Tumour grade
b (ordinal) 3.42 1.31–8.94 0.012 3.83 1.82–8.07 o0.001
Histological type
c (ordinal) 2.31 1.12–4.78 0.024 1.67 1.03–2.71 0.037
Age
d (ordinal) 2.76 0.97–7.87 0.057 1.98 1.02–3.87 0.045
Abbreviations: 95% CI¼95% confidence interval; HR¼hazard ratio; OS¼overall survival; RFS¼recurrence-free survival.
aClinical stage: late vs early stage.
bTumour grade: poor
vs well differentiated.
cHistological type : serous vs non-serous.
dAge: X50 vs o50.
Table 3 Multivariate Cox regression analysis of KLK6 expression
RFS OS
Variable HR 95% CI P-value HR 95% CI P-value
Multivariate analysis
KLK6
Low 1.00 — — 1.00 — —
High 3.03 1.05–8.74 0.040 1.45 0.81–2.60 0.215
Clinical stage
a (ordinal) 8.57 2.45–30.05 0.001 3.73 1.70–8.18 0.001
Tumour grade
b (ordinal) 1.48 0.52–4.16 0.457 2.08 0.94–4.63 0.073
Histological type
c (ordinal) 1.92 0.91–4.04 0.087 1.25 0.77–2.04 0.367
Age
d (ordinal) 2.19 0.72–6.67 0.167 1.47 0.74–2.94 0.271
Abbreviations: 95% CI¼95% confidence interval; HR¼hazard ratio; OS¼overall survival; RFS¼recurrence-free survival.
aClinical stage: late vs early stage.
bTumour grade: poor
vs well differentiated.
cHistological type : serous vs non-serous.
dAge: X50 vs o50.
KLK13 low (n=64)
No. events = 35
No. censored = 29
KLK13 high (n=41)
No. events = 20
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Figure 3 Kaplan–Meier survival curves showing the proportion of patients who are recurrence free (A) and alive (B) at the given time following
diagnosis. Patients are stratified based on KLK13 expression and compared by the log-rank test. Patients whose tumours are KLK13 low are represented with
the broken line, whereas patients whose tumours are KLK13 high are represented by the solid line. n, number of patients.
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Unlike other reproductive malignancies, such as prostate cancer,
ovarian cancer lacks a biomarker that may be used for screening.
Currently, CA125, the only marker used in ovarian cancer patients,
is reliable only for monitoring response to treatment and disease
recurrence. The identification of early biomarkers for ovarian
cancer may lead to novel therapeutic applications and potential
screening tests. This study was aimed at examining the expression
of KLK6 and KLK13 in ovarian cancer to determine their
diagnostic or prognostic value.
When we examined kallikrein protein expression by immuno-
histochemistry (Figure 1), we found that although there appeared
to be increased KLK6 and KLK13 expression in ovarian cancer
tumours relative to normal OSE, there were no significant
associations to clinical variables or survival. These results are
similar to previous studies that found increased expression of
KLK6 in primary pancreatic ductal adenocarcinoma (Ruckert et al,
2008) and salivary gland tumours (Darling et al, 2006), but found
no significant association with survival. Kallikreins 6 and 13 are
expressed in normal epithelium (Petraki et al, 2001, 2003),
including the OSE as we have shown here. Ovarian cancer is
thought to arise from either OSE or OSE cells bordering inclusion
cysts (Kaku et al, 2003), therefore it is expected that ovarian cancer
cells would express a basal level of kallikrein expression. Given the
semi-quantitative nature of immunohistochemistry and the fact
that KLKs are secreted proteins, to see a significant difference in
the cellular levels between normal OSE and ovarian cancer would
require not only changes in KLK protein production, but also a
significant change in the rate of kallikrein exocytosis.
With these limitations in quantifying protein expression, we
used qRT-PCR to assess kallikrein mRNA expression in ovarian
cancer tissues. High KLK6 mRNA expression was associated with
the presence of serous ovarian cancer and late stage disease. These
results are similar to previous studies, which found increased
KLK6 expression in ovarian cancers when compared to normal
ovarian tissue (Anisowicz et al, 1996; Tanimoto et al, 2001; Ni et al,
2004). Interestingly, previous studies have also associated high
KLK6 serum levels with advanced ovarian cancer (stage III/IV) and
serous tumour histology (Hoffman et al, 2002; Shan et al, 2007).
Ovarian serous tumours of borderline and low grade are thought
to arise from a step-wise progression from adenoma to borderline
tumour to carcinoma through the Ras-Raf signalling pathway (Bell,
2005). Recently, KLK6 expression and secretion has been shown to
be Ras dependent in a colon carcinoma cell line (Henkhaus et al,
2008). Constitutively active mutant K-Ras resulted in enhanced
colon cancer cell invasion through both laminin and Matrigel
matrixes. Together, these data suggest that Ras-Raf mutations may
increase the invasive potential of these borderline tumours
through increased expression of KLK6. This may also hold true
for advanced ovarian cancers, as we show high KLK6 expression is
associated with later stage, more invasive, cancers. High-grade
serous carcinomas have a notably different pathogenesis than low-
grade serous tumours. High-grade serous tumours commonly have
mutations in p53, BRCA 1, and/or BRCA2 (Christie and Oehler,
2006). To date there have be no reports indicating a relationship
between KLK6 and p53 or BRCA genes. When we looked at only
high- and low-grade serous tumours, we found no significant
differences in KLK6 expression (P¼0.498). Despite the apparent
differences in the molecular oncogenesis of low- and high-grade
serous tumours, their upregulation of KLK6 suggests a common
pathway is activated in both types of tumours.
Our study is the first to report KLK13 mRNA expression in normal
ovary and ovarian cancer patients. The expression of KLK13 mRNA
in normal OSE was extremely low, whereas 55% ovarian cancers
examined had high KLK13 expression. These findings support
Kapadia et al (2003), who found serum levels of KLK13 were below
levels of detection in healthy individuals, yet 50% ovarian cancer
patients were positive for KLK13 (Kapadia et al, 2003). Interestingly,
100% of our endometrioid cancer samples were high grade and
expressed KLK13 at a high level. Although our sample size is small
(six cases), this expression pattern warrants further investigation.
Low-grade endometrioid carcinomas have been suggested to arise
from endometriosis or borderline endometrioid tumours (Obata
et al, 1998), whereas high-grade endometrioid carcinomas have
changes similar to high-grade serous carcinomas (Bell, 2005;
Giordano et al, 2008; Press et al, 2008) suggesting endometrioid
cancers may represent two separate malignancies. This characteristic
expression pattern of KLK13 may represent not only a novel marker
to distinguish between high- and low-grade endometrioid cancers,
but a unique pathway in which KLK13 may be involved in ovarian
carcinogenesis.
Since histological types of ovarian cancers present as a spectrum
of pathologically and histologically different phenotypes and may
represent cancers of different origins (Bell, 2005), the possibility
that a panel of markers, rather than a single marker, may improve
the sensitivity and specificity of detecting ovarian cancer at an
early stage while it is treatable. Zheng et al (2007) found that a
group of kallikrein-related peptidases, including KLK6 and KLK13,
in multi-parametric combinations with other biomarkers and
clinical variables can significantly predict prognosis and response
to treatment in ovarian cancer patients. A similar model, including
a number of kallikrein-related peptidases, has been proposed for
non-small-cell lung carcinoma (Planque et al, 2008). This study
confirms both KLK6 and KLK13 are overexpressed in ovarian
cancer and are useful predictors of poor prognosis in ovarian
cancer patients. This study is the first to report upregulation of
KLK13 mRNA in ovarian cancer patients and indicated that KLK13
may represent a specific marker for endometrioid carcinoma.
These findings support the potential role as kallikrein-related
peptidases 6 and 13 as novel ovarian cancer biomarkers and may,
in the future, offer targets for therapeutic applications.
Table 4 Multivariate Cox regression analysis of KLK13 expression
RFS OS
Variable HR 95% CI P-value HR 95% CI P-value
Multivariate analysis
KLK13
Low 1.00 — — 1.00 — —
High 2.20 1.01–4.78 0.047 1.00 0.61–1.61 0.988
Clinical stage
a (ordinal) 9.08 2.61–31.65 0.001 4.00 1.84–8.70 o0.001
Tumour grade
b (ordinal) 1.22 0.42–3.55 0.717 2.14 0.95–4.81 0.065
Histological type
c (ordinal) 2.43 1.13–5.24 0.024 1.29 0.79–2.10 0.308
Age
d (ordinal) 2.49 0.82–7.54 0.108 1.46 0.73–2.91 0.286
Abbreviations: 95% CI¼95% confidence interval; HR¼hazard ratio; OS¼overall survival; RFS¼recurrence-free survival.
aClinical stage: late vs early stage.
bTumour grade: poor
vs well differentiated.
cHistological type : serous vs non-serous.
dAge: X50 vs o50.
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